Tumor microenvironment responsive Mn$_3$O$_4$ nanoplatform for in vivo real-time monitoring of drug resistance and photothermal/chemodynamic synergistic therapy of gastric cancer

Hanrui Li$^1$, Xiaoxia Cai$^1$, Tong Yi$^1$, Yun Zeng$^1$, Jingwen Ma$^2$, Lei Li$^2$, Liaojun Pang$^1$, Na Li$^2$, Hao Hu$^3$ and Yonghua Zhan$^1$*

Abstract
Background: Postoperative chemotherapy for gastric cancer often causes multidrug resistance (MDR), which has serious consequences for therapeutic effects. Individualized treatment based on accurate monitoring of MDR will greatly improve patient survival.

Results: In this article, a self-enhanced Mn$_3$O$_4$ nanoplatform (MPG NPs) was established, which can react with glutathione to produce Mn$^{2+}$ to enhance T1-weighted magnetic resonance imaging (MRI) and mediate in vivo real-time MDR monitoring. In vitro MRI results showed that MRI signals could be enhanced in the presence of hydrogen peroxide and glutathione and at acidic pH. In vivo MRI results indicated that MPG NPs could specifically target MDR cells, thereby realizing real-time monitoring of MDR in gastric cancer. Furthermore, MPG NPs have good chemodynamic activity, which can convert the endogenous hydrogen peroxide of tumor cells into highly toxic hydroxyl radical through Fenton-like reaction at acidic pH to play the role of chemodynamic therapy. In addition, Mn$_3$O$_4$ can significantly enhance the chemodynamic therapy effect because of its good photothermal conversion effect. Furthermore, in situ photothermal/chemodynamic synergistic therapy obtained remarkable results, the tumors of the mice in the synergistic therapy group gradually became smaller or even disappeared.

Conclusions: MPG NPs have good biocompatibility, providing a good nanoplatform for real-time monitoring and precise diagnosis and treatment of MDR in gastric cancer.

Keywords: Gastric cancer, Multidrug resistance, Fenton-like reaction, Chemodynamic therapy, Photothermal therapy, Self-enhanced nanoplatform
Background
Gastric cancer is the fifth most common cancer in the world and seriously threatens human health [1]. Chemotherapy is the main adjuvant treatment after surgery. However, long-term chemotherapy easily induces multidrug resistance (MDR), which seriously influences treatment effects. Therefore, accurate monitoring of MDR is essential for the treatment of gastric cancer. In past studies, several MDR evaluation methods have been described, such as fresh tumor cell culture tests and cancer biomarker tests [2, 3]. These methods use fresh tumor cells to perform effective chemotherapy MDR detection in vitro or evaluate MDR through the expression of marker proteins. However, to a certain extent, such methods cannot reflect the real state of MDR. In addition, there have been studies using molecular imaging technology to perform in vivo imaging and to evaluate the degree of MDR through changes in tumor size after drug treatment [4]. The noninvasiveness of molecular imaging offers a good way to monitor MDR. However, delayed anatomical changes often cannot evaluate MDR in real time. Therefore, it is urgent to explore a new method to monitor MDR. As a new type of specific peptide, GMBP1 can specifically bind to the GRP78 receptor overexpressed on the surface of MDR gastric cancer cells [5] and significantly downregulate the levels of eukaryotic translation initiation factor 4E (EIF4E) and C-terminal binding protein 2 (CTBP2), thereby regulating the MDR phenotype of gastric cancer [6], which has been preliminarily proven to have a good ability to detect MDR gastric cancer [7]. Once MDR is accurately detected, individualized treatment can be implemented for patients, which can greatly improve the postoperative survival rate of patients. The individualized treatment of MDR gastric cancer commonly used in the clinic includes replacing new chemotherapeutic drugs or using adjuvant radiotherapy. However, the high cost and long-term and uncertain therapeutic effects of new drug development, as well as the regional limitations and body damage of radiotherapy, result in many difficulties associated with the clinical treatment of MDR gastric cancer that cannot be ignored [8, 9]. Therefore, it is important to explore other effective treatments for MDR in gastric cancer.

Studies have shown that the mechanism of MDR is closely related to the tumor microenvironment (TME), and due to the complexity and diversity of MDR, tumor treatment strategies for the TME have been applied to combat MDR tumors [10]. Among them, inducing intracellular ROS production is an effective tumor treatment method. High levels of ROS cause oxidative damage to cells, leading to cell death [11]. The Fenton reaction can use a Fenton catalyst to oxidize metal ions and convert hydrogen peroxide (H₂O₂) with low endogenous reactivity into highly toxic hydroxyl radicals (-OH) under acidic conditions to kill tumor cells, which makes chemodynamic therapy (CDT) based on the Fenton reaction a new and thriving tumor treatment strategy with its noninvasiveness and high selectivity [12, 13]. At present, some nanoparticles based on metal ions (such as Fe²⁺, Mn²⁺, Cu²⁺, etc.) have been used as CDT agents to induce
tumor apoptosis. Unfortunately, the effects of CDT based on these nanoparticles are often limited by poor catalytic efficiency and low \( \text{H}_2\text{O}_2 \) concentration in the TME. In addition, a large amount of GSH in tumor cells eliminates \( \cdot \text{OH} \), which will greatly weaken the effect of CDT [12, 14]. Therefore, the development of new therapeutic agents that can increase the efficiency of CDT and reduce the content of GSH in cells is of great significance for improving the efficacy of CDT.

The rapid development of nanomaterials provides a new opportunity for precise diagnosis and individualized treatment of tumors, such as polymeric nanoparticles, liposome, metal nanoparticles, 3D printing nanomaterials [15–25]. Among them, manganese oxide nanoparticles (NPs) have become a good choice for tumor diagnosis and treatment due to their good biocompatibility, in vivo imaging performance and TME responsiveness [26]. For example, Lin et al. synthesized \( \text{MnO}_2 \)-coated mesoporous \( \text{SiO}_2 \) for Fenton-like reaction \( \text{Mn}^{2+} \) delivery and GSH depletion to enhance the brain glioma CDT effect, and CDT monitoring was carried out by in vivo MRI [12]. In addition, it is worth noting that \( \text{Mn}_3\text{O}_4 \) contains \( \text{Mn}^{2+} \) and \( \text{Mn}^{3+} \). It has been reported that \( \text{Mn}_3\text{O}_4 \) is highly sensitive to the redox environment in the cell and is easily decomposed when exposed to GSH. The \( \text{Mn}^{2+} \) generated after the decomposition of \( \text{Mn}_3\text{O}_4 \) enhances T1-weighted MRI [27]. Therefore, it is reasonable to speculate that magnetic \( \text{Mn}_3\text{O}_4 \) can not only achieve tumor self-enhanced CDT but can also be used as a T1-enhanced MRI contrast agent. Last but not least, studies have shown that \( \text{Mn}_3\text{O}_4 \) has wide absorption in the near-infrared region and can be used as a new type of inorganic photothermal conversion nanoagent for photothermal therapy (PTT) of tumors [28]. Meanwhile, PTT increases the efficiency of the Fenton reaction and the productivity of \( \cdot \text{OH} \) by heating the tumor locally, thereby overcoming the problem of poor CDT effect caused by the limited content of endogenous \( \text{H}_2\text{O}_2 \) and GSH in tumor cells [13]. Therefore, the combination of CDT and PTT based on \( \text{Mn}_3\text{O}_4 \) as a contrast agent undoubtedly provides a reliable choice for the treatment of MDR gastric cancer. However, there is no related research on CDT/PTT synergistic therapy for MDR gastric cancer based on \( \text{Mn}_3\text{O}_4 \). In view of this, the establishment of a multifunctional self-enhanced nanoplatform based on \( \text{Mn}_3\text{O}_4 \) NPs plays a very important role in the accurate monitoring and individualized treatment of MDR in gastric cancer.

Here, we report a GMBP1-modified \( \text{pH}/\text{H}_2\text{O}_2/\text{GSH} \)-responsive \( \text{Mn}_3\text{O}_4 \) multifunctional self-enhanced nanoplatform with Fenton-like \( \text{Mn}^{2+} \) delivery, GSH depletion properties and photothermal conversion properties for in vivo real-time monitoring of MDR and in situ CDT/PTT synergistic therapy, which provides a good nanoplatform for the clinical treatment of MDR gastric cancer. Multifunctional \( \text{Mn}_3\text{O}_4 \) NPs were coated with polydopamine (PDA) to form \( \text{Mn}_3\text{O}_4@\text{PDA} \) NPs to improve their biocompatibility and enhance the effect of PTT [29]. At the same time, to achieve accurate monitoring of MDR in gastric cancer, GMBP1 was coupled to the surface of \( \text{Mn}_3\text{O}_4@\text{PDA} \) NPs through photoclick chemistry, and multifunctional composite MPG NPs were prepared. After MPG NPs are internalized into MDR gastric cancer cells, \( \text{Mn}_3\text{O}_4 \) NPs will undergo a redox reaction with GSH in the cells to generate \( \text{Mn}^{2+} \) with excellent Fenton-like activity, thereby converting endogenous \( \text{H}_2\text{O}_2 \) into highly toxic \( \cdot \text{OH} \). The consumption of the antioxidant GSH in the cell prevents the elimination of \( \cdot \text{OH} \), which leads to the enhancement of CDT. At the same time, the undissociated \( \text{Mn}_3\text{O}_4@\text{PDA} \) NPs produce a photothermal effect triggered by the 808 nm NIR laser, which enhances the CDT effect. In addition, \( \text{Mn}^{2+} \) with higher longitudinal relaxation properties gives \( \text{Mn}_3\text{O}_4 \) NPs an enhanced MRI contrast effect activated by \( \text{pH}/\text{H}_2\text{O}_2/\text{GSH} \). MPG NPs will provide a new nanoplatform for the accurate monitoring and individualized treatment of MDR in gastric cancer.

Results and discussion

Accurate monitoring of MDR is very important for individualized treatment of gastric cancer. There have been methods to assess MDR in past studies, such as fresh tumor cell culture tests, cancer biomarker tests, or in vivo tumor imaging to assess the degree of MDR. However, to a certain extent, these methods cannot reflect the real state of MDR in real time. Therefore, it is necessary to explore new methods for real-time monitoring of MDR. Once MDR is monitored, individualized treatment can be performed on MDR gastric cancer patients to improve their survival rate. In view of this, a GMBP1 cross-linked self-enhanced nanoplatform of \( \text{Mn}_3\text{O}_4 \) NPs with a GSH consumption function was established, which can react with GSH to generate \( \text{Mn}^{2+} \) to enhance T1-weighted MRI, thereby mediating in vivo MDR monitoring. As a Fenton-like reagent, \( \text{Mn}^{2+} \) can convert \( \text{H}_2\text{O}_2 \) in cells into highly toxic \( \cdot \text{OH} \), which can exert a CDT effect. \( \text{Mn}_3\text{O}_4 \) NPs can also be used as photothermal conversion agents for PTT, which can effectively improve Fenton reaction efficiency and the production of \( \cdot \text{OH} \), thereby enhancing the CDT effect. MPG NPs achieved in vivo CDT/PTT synergistic therapy, providing a good nanoplatform for the treatment of MDR gastric cancer (Fig. 1).

Preparation and characterization of MPG NPs

The synthesis scheme of MPG NPs is shown in Fig. 2A. Among them, \( \text{Mn}_3\text{O}_4 \) NPs were synthesized according to
the thermal decomposition method described in a previous study [30]. As shown in the TEM image of Fig. 2B, the Mn₃O₄ NPs dispersed in the organic solvent present a spherical structure with uniform particle size, good dispersibility, and a particle size of approximately 7.4 ± 0.21 nm. The Mn₃O₄ NPs can be well dispersed in water after being coated with PDA. The particle size of Mn₃O₄ NPs coated with the PDA layer is slightly larger, approximately 8.2 ± 0.27 nm, and the PDA coating on the surface can be observed clearly (illustration) (Fig. 2C). The crystal form of Mn₃O₄ NPs was verified by XRD (Fig. 2D). The results show that the diffraction peaks of the synthesized Mn₃O₄ NPs are basically coincident with the diffraction peaks of Joint Committee on Powder Diffraction Standards (JCPDS) Card No. 24–0734, which belong to the tetragonal system. The synthetic method of tetrazole compound T is shown in Additional file 1: Fig. S1A. To verify the successful synthesis of Mn₃O₄ NPs, the mass spectrum (Additional file 1: Fig. S1B) and ¹³C NMR spectrum (Additional file 1: Fig. S1C) of T were obtained. ESI-MS: m/z 339.1 [M + H]^+; ¹³C NMR (150 MHz, DMSO-d₆) δ = 38.45, 38.59, 55.06, 114.47, 121.08, 125.75, 135.89, 159.83, 163.05, 164.19, 164.98. The amino group of T and the oxidation state quinone on the surface of PDA form a covalent graft through the Schiff base reaction. The reaction easily proceeds without complicated equipment and harsh conditions [31]. As shown in the ultraviolet absorption spectrum of Fig. 2E, tetrazole compound T has a maximum absorption peak at 290 nm. After the photoclick reaction between T and GMBP1-Ack, there is a maximum absorption peak at approximately 370 nm. This is due to the formation of new pyrazoline products after the photoclick reaction [32]. Mn₃O₄@PDA NPs have no characteristic peak of ultraviolet absorption. Mn₃O₄@PDA-T NPs had the maximum absorption peak at approximately 285 nm, which proved the successful crosslinking of T. After the photoclick reaction between Mn₃O₄@PDA-T and GMBP1-Ack, there was a maximum absorption peak at approximately 365 nm. The blueshift of the absorption of Mn₃O₄@PDA-T NPs may be caused by the steric hindrance of PDA. These results initially proved the successful synthesis of MPG NPs. As shown in the fluorescence spectrum of Fig. 2F, under 410 nm laser excitation, the maximum emission wavelength after the photoclick reaction of T and GMBP1-Ack is approximately 535 nm, and the maximum emission wavelength of MPG NPs is approximately 545 nm. This is due to the fluorescent pyrazoline product produced by the photoclick reaction. As shown in Fig. 2, G and H, the hydrated particle size and zeta potential of Mn₃O₄@PDA NPs, Mn₃O₄@PDA-T NPs and MPG NPs were measured by a Malvern particle size analyzer. The results show that the hydrated particle size of Mn₃O₄@PDA NPs is approximately 32.7 ± 4.8 nm, and the potential is −15 mV. The negative potential of Mn₃O₄@PDA NPs is attributed to the quinoneimine and catechol groups on the surface of PDA. The reversible dissociation and deprotonation/protonation of the amine and catechol groups make PDA generate a positive or negative charge, and the net charge is negative [33].
After crosslinking T on the surface of Mn$_3$O$_4$@PDA NPs, the hydrated particle size increases to approximately 37.8 ± 5.6 nm, and the potential tends to be neutral. After the photoclick reaction between Mn$_3$O$_4$@PDA-T NPs and GMBP1-Ack, the particle size continues to increase to approximately 50.5 ± 3.7 nm, which is due to the influence of the surface hydration layer, and the potential has also become +3 mV. The stability of nanoparticles is an important factor for in vivo long-term imaging studies. The MPG NPs were dispersed in PBS and 10% FBS, and the changes in particle size at different temperatures were measured to verify the stability of the MPG NPs. As shown in Fig. 2I, the particle size of MPG NPs did not change significantly within 6 days, and the solution remained clear. The results indicate that MPG NPs have good stability.

**In vitro MRI and fluorescence imaging of MPG NPs**

To test the MRI contrast ability of MPG NPs, the relaxation characteristics of Mn$_3$O$_4$@PDA NPs and MPG NPs...
were measured with MRI scanner (0.5 T). As shown in Fig. 3A, as the concentration of Mn3O4 NPs increased, Mn3O4@PDA NPs and MPG NPs both showed signal enhancement in the T1-weighted MRI image. According to the linear fit of 1/T1 to the concentration of Mn3O4 NPs, the r1 values of Mn3O4@PDA NPs and MPG NPs were calculated to be 0.606 mM⁻¹s⁻¹ and 0.461 mM⁻¹s⁻¹, respectively (Fig. 3B). PDA modification enhances the T1 relaxivity of Mn3O4 NPs, and its r1 value is more than 3 times higher than that of Mn3O4@PEG NPs (0.2 mM⁻¹s⁻¹) [7], confirming the potential use of Mn3O4@PDA NPs as MRI imaging agents. The r1 value of MPG NPs is lower than that of Mn3O4@PDA NPs. The main reason for this result is that the connection of T on the surface of PDA reduces the contact of water protons with Mn3O4 nuclei, thereby weakening the T1 relaxation properties of NPs. Although the r1 value of MPG NPs is reduced, it is still higher than that of Mn3O4@PEG NPs, indicating that it has the ability for in vivo MRI. At the same time, the in vitro fluorescence imaging performance of MPG NPs was tested by the PerkinElmer IVIS system. As shown in Fig. 3A, as the concentration of MPG NPs increased, the fluorescence signal increased, which was consistent with the result of fluorescence signal.

Fig. 3  In vitro MRI and fluorescence imaging of MPG NPs. A MRI and fluorescence imaging of different concentrations of Mn3O4@PDA NPs and MPG NPs. B MRI relaxation rate and fluorescence intensity of Mn3O4@PDA NPs and MPG NPs at different concentrations. C MRI of different concentrations of MPG NPs at different pH values. D MRI relaxation rate of MPG NPs at different concentrations and different pH values. E MRI of different concentrations of MPG NPs with H2O2 at different pH values. F MRI relaxation rate of MPG NPs with H2O2 at different concentrations and different pH values. G MRI of different concentrations of MPG NPs with or without GSH. H MRI relaxation rate of MPG NPs with or without GSH at different concentrations.
also attributed to the catalytic reaction of H2O2 reduction resulting in a lower pH in tumor tissues and weak acid-upregulated to produce a large amount of lactic acid, during tumor growth, glycolysis and metabolism are upregulated to produce a large amount of lactic acid, resulting in a lower pH in tumor tissues and weak acidity of the TME [36]. To simulate the blood environment and TME, the pH values were set to 7.4, 6.0 and 5.0 [37].

The relaxation images and relaxation times of MPG NPs at different pH values were measured, and the relaxation rate was calculated. As shown in Fig. 3C, under the same pH conditions, with increasing Mn3O4 concentration in MPG NPs, the MRI signal gradually increased. At the same Mn3O4 concentration, the lower the pH value, the stronger the MRI signal. Figure 3D shows the relaxation rate at different pH values. The results show that the relaxation rate r1 is only 0.505 mM−1s−1 at pH 7.4 and 0.779 mM−1s−1 at pH 6.0. When the pH value is 5.0, the relaxation rate can reach 1.321 mM−1s−1, which is 2.6 times that under neutral conditions. These results indicated that the synthesized MPG NPs are sufficiently sensitive to acidic environments. Under acidic conditions, the MRI signal increases significantly, the relaxation time becomes shorter, and the relaxation rate increases. Furthermore, MPG NPs can be used as excellent pH-responsive T1-weighted MRI agents.

Furthermore, H2O2 is overproduced in malignant tumor cells, leading to a significant increase in H2O2 in the TME [38]. There have been reports of H2O2 dissociating MnO2 into O2 and Mn2+ under weak acid conditions to enhance T1-weighted MRI [39, 40], but there is no report in terms of Mn3O4-related research. Therefore, the T1-MRI performance of Mn3O4 under H2O2 conditions was explored. In Fig. 3E, it is observed that MPG NPs have strong concentration-dependent signal enhancement. In addition, the relaxation rate of MPG NPs at pH 6.8 (r1 = 1.009 mM−1s−1) is 1.9 times that at pH 7.4 (r1 = 0.5063 mM−1s−1) (Fig. 3F), indicating that protons are essential in the decomposition of Mn3O4 induced by H2O2. At the same time, after adding H2O2, the T1 enhancement obtained in the presence of H+ is also attributed to the catalytic reaction of H2O2 reduction [41, 42].

In addition, GSH in tumor tissue is 5 times that of normal tissue, and GSH plays a key role in protecting cells from various harmful substances (such as H2O2, superoxide, ·OH and other active substances) [12]. To evaluate the effectiveness of MPG NPs as GSH-activated T1 contrast agents, MPG NPs were dispersed in a solution containing GSH (15 mM) and incubated for 5 min, and T1-weighted MRI images were obtained (Fig. 3G). In the presence of GSH, T1-weighted MRI images of MPG NPs showed stronger signal enhancement than MPG NP solutions without GSH, and the r1 relaxation rate was increased by 7.4 times (Fig. 3H). The enhancement of the relaxation rate is due to the release of Mn2+ after the redox reaction between Mn3O4 NPs and GSH, and the water coordination number in the center of Mn increases, which leads to the enhancement of the T1-weighted MRI signal [27]. The above results proved that MPG NPs have the potential to respond to TME and enhance MRI, which can be used as good self-enhanced nanoprotocols.

**In vitro chemodynamic activity of MPG NPs**

The occurrence of MDR is closely related to TME. To verify whether MPG NPs can respond to the TME and exert in vivo CDT effect, the chemodynamic activity of MPG NPs was studied in vitro. First, it was verified that Mn2+ can react with H2O2 to produce ·OH through a Fenton-like reaction in the presence of HCO3−, thereby degrading methylene blue (MB). It can be seen from Fig. 4A and B that when Mn2+ and H2O2 are incubated in NaHCO3/CO2 buffer for 30 min, the absorbance of MB at 665 nm is significantly reduced, and the presence of Mn2+ or H2O2 alone has no significant effect on the absorbance of MB. In aqueous solution, the absorbance value of MB did not change significantly. As the concentration of H2O2 increased, the absorbance of MB gradually decreased (Fig. 4C). These results show that the Mn2+-mediated Fenton-like reaction can effectively produce ·OH under physiological NaHCO3/CO2 conditions, which is consistent with previous research [12]. In Fig. 4D, in the presence of 10 mM GSH, the absorbance value of MB did not significantly decrease, which indicates that ·OH-induced MB degradation was significantly inhibited in the presence of 10 mM GSH. With increasing GSH concentration (0–10 mM), the absorbance value of MB gradually increased, indicating that the degradation of MB was gradually inhibited (Fig. 4E). The remaining amount of MB in each group is shown in Additional file 1: Fig. S2A. Next, the chemodynamic activity of Mn3O4@PEG NPs was verified. In previous studies, the color of the MnO2 solution gradually disappeared after gradually adding different concentrations of GSH solution, and it was proven that MnO2 reacted with GSH to produce Mn2+ and GSSG. Different concentrations of GSH solution were gradually added to the Mn3O4@PEG NP solution, and the color of the solution gradually became lighter (Additional file 1: Fig. S2B), and the reaction efficiency with
GSH was significantly higher than that of pH-triggered reactions (Additional file 1: Fig. S2C), which is consistent with a previous study [12]. Figure 4F shows that as the concentration of GSH in the Mn$_3$O$_4$@PEG NP solution increases, the absorbance value of MB gradually decreases. When the concentration of GSH reaches 12 mM, the absorbance value of MB gradually increases, indicating that Mn$_3$O$_4$ NPs react with GSH to produce Mn$^{2+}$, which reacts with H$_2$O$_2$ to produce ·OH through a Fenton-like reaction. However, with the increase in free GSH, the ·OH that produced by the Fenton-like reaction is gradually eliminated, thereby inhibiting the degradation of MB (Fig. 4G). Figure 4H shows the degradation of MB after adding different concentrations of GSH to the MPG NP solution. The results show that as the concentration of GSH increases, the absorbance of MB decreases first and then increases gradually, which is consistent with the above results [12]. The degradation efficiency of MB by ·OH in the presence of GSH is shown in Additional file 1: Fig. S2, D to F. The results show that when the GSH concentration was as high as 10 mM, Mn$_3$O$_4$@PEG NPs still showed 57.69% MB degradation efficiency, which is approximately 3 times the MB degradation efficiency promoted by Mn$^{2+}$ (18.8%) under...
the same conditions. MPG NPs showed 39.92% MB degradation efficiency, which is approximately 2.12 times the MB degradation efficiency promoted by Mn$^{2+}$ under the same conditions. These results indicate that MPG NPs have good in vitro chemodynamic activity and have the potential for in vivo CDT.

The above experiments have proven that Mn$_3$O$_4$ NPs can generate Mn$^{2+}$ in the presence of GSH and enhance MRI. Mn$^{2+}$ can convert H$_2$O$_2$ into highly toxic ·OH to kill tumor cells (Fig. 4l). The production of ROS in the presence of MPG NPs was verified in the cell. Figure 4j shows the observation of ROS production by detecting cell DCF fluorescence after adding different materials. DCFH-DA has no fluorescence and is hydrolyzed into DCF after entering cells and then rapidly oxidized to DCF with fluorescence [43]. The fluorescence intensity of DCF shows that in the presence of manganese ions, the fluorescence of DCF is significantly stronger than that of the control group. The quantitative analysis of the mean fluorescence intensity (MFI) is shown in Additional file 1: Fig. S2G. The results showed that the DCF fluorescence intensity of cells coincubated with MPG NPs was significantly different from that of the other groups. This indicates that MPG NPs react with GSH in cells to generate Mn$^{2+}$, which mediates the Fenton-like reaction and generates ROS. It not only reduces the elimination of ·OH by GSH but also produces more ROS and enhances the killing effect on tumor cells.

**In vitro and in vivo photothermal effect of MPG NPs**

Studies have shown that Mn$_3$O$_4$ NPs have high molar extinction coefficient and strong absorption in the near-infrared region [28, 44], which can be used for in vivo PTT. In addition, PTT can increase the efficiency of the Fenton reaction and the productivity of ·OH by locally heating the tumor [13]. To verify whether MPG NPs can be used for in vivo PTT, the photothermal effect of MPG NPs was verified. First, it was determined whether Mn$_3$O$_4$ NPs have photothermal effects and enhanced in vivo PTT. The temperature changes of different concentrations of Mn$_3$O$_4@$PEG NPs irradiated with 808 nm lasers with different powers for 5 min were measured. As shown in Fig. 5A, under laser irradiation (1 W), the temperature of the aqueous solution does not change much. As the Mn$_3$O$_4@$PEG NP concentration increases, the temperature gradually increases. As shown in Fig. 5B, as the laser power increases, the temperature of the Mn$_3$O$_4@$PEG NP solution (1 mg mL$^{-1}$) gradually increases. These results indicate that Mn$_3$O$_4@$PEG NPs have certain photothermal properties. As shown in Fig. 5C, the temperature change of the solution of the same concentration of Mn$_3$O$_4@$PEG NPs, PDA and MPG NPs (1 mg mL$^{-1}$) was measured after 808 nm laser irradiation (2 W) for 5 min. The results show that the temperature of MPG NPs increases the fastest, and the temperature can reach 55 °C after 5 min. Compared with Mn$_3$O$_4@$PEG NPs and PDA, MPG NPs have better photothermal performance. To detect the influence of laser power on the photothermal effect of MPG NPs, the temperature change of MPG NPs under different laser powers for 5 min was measured. As shown in Fig. 5D, when the laser power is 0.5 W, the temperature of the MPG NP solution does not change much. As the power increases, the temperature gradually increases. When the power reaches 2 W, the temperature of the MPG NP solution can reach 55 °C after 5 min of irradiation. To verify the influence of the concentration on the photothermal effect of MPG NPs, the temperature changes of MPG NP solutions of different concentrations under 808 nm laser irradiation (1 W) for 5 min were measured. The solution without MPG NPs was used as a control. As shown in Fig. 5E, after 5 min of laser irradiation, the temperature of the control solution did not change much, and the temperature gradually increased as the concentration increased. To verify whether MPG NPs have good photothermal cycling properties, the MPG NP solution was first irradiated with a laser (2 W) for 5 min, and then irradiation was stopped and returned to room temperature. The cycle was repeated 5 times. As shown in Fig. 5F, the temperature of the MPG NP solution can rise above 50 °C after each irradiation and return to room temperature within a certain period of time. The results show that laser irradiation does not affect the photothermal performance of MPG NPs.

To verify the in vivo photothermal effect of MPG NPs, photothermal images of the tumor-bearing mice before and after laser irradiation were obtained. Figure 5G shows that the temperature of the tumor site of the mice in the PBS injection group did not increase significantly after laser irradiation and only increased from 35.4 to 37.9 °C. The tumor site temperature of mice injected with Mn$_3$O$_4@$PDA NPs increased from 35.8 to 43.1 °C. The fastest increase in temperature was observed in the mice injected with MPG NPs. The temperature of the tumor site increased from 35.7 to 44.7 °C, which also proved that MPG NPs demonstrate good targeting of MDR gastric cancer cells, allowing more MPG NPs to gather at the tumor sites to exert the better PTT effect. All of the above results indicate that MPG NPs have a good in vitro and in vivo photothermal effect and can release heat under laser irradiation after being internalized by the cells, thus causing cell death (Fig. 5H).

**Cellular uptake and affinity analysis**

To verify whether MPG NPs can be used for in vivo MDR monitoring, cell uptake and affinity analyses were first performed. SGC 7901 ADR cells were used for
internalization analysis, and the cell affinity of MPG NPs was verified in SGC 7901 ADR and SGC 7901 cell lines. The same concentration of MPG NPs was incubated with SGC 7901 ADR cells for different times, and the fluorescence intensity was observed by confocal microscopy. As shown in Additional file 1: Fig. S3A, blue represents the fluorescence of DAPI, and green represents the fluorescence of MPG NPs. The results showed that with increasing incubation time, the green fluorescence gradually increased, and the green fluorescence was mainly distributed in the cytoplasm, which indicated that MPG NPs were gradually internalized into the cytoplasm. The quantification of fluorescence intensity in Additional file 1: Fig. S3C also shows the same result. A cell affinity experiment was used to verify the specific targeting ability of MPG NPs on MDR gastric cancer cells. As shown in Additional file 1: Fig. S3B, in SGC 7901 ADR cells, the green fluorescence intensity after blocking with GMBP1 was significantly lower than the fluorescence intensity after MPG NP incubation. In SGC 7901 cells, the green fluorescence intensity after blocking with GMBP1 was not significantly different from the fluorescence intensity directly incubated with MPG NPs. The above results indicate that GMBP1 has the ability to specifically target SGC 7901 ADR cells because GMBP1 can specifically bind to the GRP78 receptor overexpressed on the surface of MDR cells [5]. The quantitative analysis shown in Additional file 1: Fig. S3D also produced the same results. The good specific targeting of MPG NPs to tumor cells also leads to less accumulation of MPG NPs.
in normal cells, thereby further reducing its in vivo toxicity. MPG NPs provide the basis for in vivo MDR monitoring and synergistic therapy with their specific tumor targeting.

Cellular inhibitory effect of MPG NPs
The toxicity and the inhibitory effect of nanomaterials on normal cells and tumor cells were evaluated by the MTT method, which is very important for MDR gastric

**Fig. 6**  Tumor cell inhibitory effect of MPG NPs. A Survival rate of HUVECs after incubation with MPG NPs. B Survival rate of SGC 7901 cells after incubation with MPG NPs. C Survival rate of SGC 7901 ADR cells after incubation with MPG NPs. D Survival rate of SGC 7901 cells incubated with MPG NPs after laser irradiation. E Survival rate of SGC 7901 ADR cells incubated with MPG NPs after laser irradiation. F Clone images of cells incubated with MPG NPs after laser irradiation. G Quantification of the number of clones in SGC 7901 ADR cells. H Quantification of the number of clones in SGC 7901 cells. I Flow cytometry of cells incubated with different concentrations of MPG NPs with or without laser irradiation. J Staining image of cells with or without laser irradiation after incubation with MPG NPs.
cancer therapy. As shown in Fig. 6A, the cytotoxicity of MPG NPs to normal cells was concentration-dependent. With increasing MPG NP concentration, the survival rate of HUVECs decreased gradually. In previous studies, cell survival was still close to 60% when the concentration of Mn₃O₄@PEG was up to 40 µg mL⁻¹ [7]. The coating of PDA significantly reduced the toxicity of Mn₃O₄ and when the concentration reached 243 µg mL⁻¹, the survival rate of normal cells after Mn₃O₄@PDA NPs treatment was still above 80%. In SGC 7901 cells, MPG NPs did not show a significant inhibitory effect on the cells (Fig. 6B), while in SGC 7901 ADR cells, MPG NPs had a significantly enhanced inhibitory effect on the cells (Fig. 6C). The results show that low concentrations of MPG NPs will not cause significant damage to normal cells, and the presence of GMBP1 reduces the cytotoxicity caused by the tetrazolium compound T. Moreover, the high uptake of MPG NPs by SGC 7901 ADR cells also increased the inhibitory effect of MPG NPs on MDR gastric cancer cells, which was attributed to the presence of GMBP1 on the surface of MPG NPs. The survival rate of the cells after laser irradiation was measured in SGC 7901 and SGC 7901 ADR cells. As shown in Fig. 6D and E, laser irradiation did not cause significant cell death in the absence of MPG NPs. With increasing MPG NP concentration, the cell survival rate decreased significantly. When the concentration of MPG NPs reached 100 µg mL⁻¹, only a few cells survived, and under laser irradiation, the inhibitory effect of MPG NPs on SGC 7901 ADR cells was significantly stronger than that of SGC 7901 cells.

The inhibitory effect of MPG NPs on tumor cells was verified by colony formation assay. Images of cell clones treated with different concentrations of MPG NPs were obtained, and the number of colonies was quantified. As shown in Fig. 6F, in SGC 7901 and SGC 7901 ADR cells, the number of cell clones in the control group was the largest. With increasing MPG NP concentration, the number of cell clones gradually decreased. Figure 6G and H show the quantification of the number of cell clones in each group. The results show that when the MPG NP concentration reaches 100 µg mL⁻¹, the number of cell clones is significantly reduced, which is a significant difference compared with the control group. The above results indicate that MPG NPs have a good photothermal effect and can inhibit the growth of tumor cells after 808 nm laser irradiation. With increasing MPG NP concentration, the photothermal effect is more obvious, and the tumor cell inhibitory effect is also more obvious.

The apoptosis of cells after incubation with different concentrations of MPG NPs was observed by flow cytometry. As shown in Fig. 6I, the cells that were not treated with MPG NPs did not show obvious apoptosis. Without laser irradiation, slight early apoptosis appeared gradually with increasing MPG NP concentration. However, after 808 nm laser irradiation for 2 min, the number of apoptotic cells increased with increasing MPG NP concentration. The results show that the photothermal effect of MPG NPs causes significant cell apoptosis, verifying the good photothermal effect and the potential of in vivo PTT of MPG NPs. The inhibitory effect of MPG NPs on SGC 7901 ADR cells was further verified by cell staining. FDA was used to stain living cells with green fluorescence, and PI was used to stain dead cells with red fluorescence. As shown in Fig. 6J, in the absence of MPG NPs, neither laser irradiation nor nonirradiation caused significant cell death. The low concentration of MPG NPs only caused a few cell deaths, which is due to the CDT effect of MPG NPs in the cells. At the same concentration of MPG NPs, the number of cell deaths increased greatly after laser irradiation, which was caused by the photothermal effect of MPG NPs after laser irradiation. All the above results indicated that MPG NPs had a significant inhibitory effect on tumor cells and had the potential for synergistic therapy in vivo.

In vivo T1-weighted MRI for MDR monitoring

In vivo MDR monitoring is very important for the individualized treatment of gastric cancer. MRI was performed to verify whether MPG NPs can be used for in vivo MDR monitoring. An orthotopic gastric cancer mouse model was established, MPG NPs were injected in vivo, and MRI signal changes were monitored for 5 h. As shown in Fig. 7A, no significant signal enhancement at the tumor site was observed in the control group. The tumor site has been marked with a circle. The MRI signal intensity of the mice in the SGC 7901 ADR group increased significantly 2 h after the injection, and the MRI signal intensity was strongest at 3 h after the injection. In the SGC 7901 group, the MRI signal intensity also increased significantly after injection, but the signal intensity was weaker than that of the SGC 7901 ADR group. In the blocking group, GMBP1 was injected first, and then MPG NPs were injected half an hour later, the MRI signal intensity did not increase significantly. This is because free GMBP1 competes with MPG NPs to bind to the GRP78 receptors on the surface of MDR gastric cancer cells, so MPG NPs cannot be enriched at the tumor site, thus showing lower MRI signal intensity. It can also be seen from the quantitative results that in SGC 7901 ADR model mice, the MRI signal increased significantly and reached the maximum signal value 3 h after injection (Additional file 1: Fig. S3E). Major organs and tumor tissues of each group of mice were obtained, and immunofluorescence staining
was performed. Figure 7B shows the staining images of each group of mice. The results showed that the fluorescence intensity of MPG NPs in the SGC 7901 ADR mouse model was significantly higher than that in the SGC 7901 mouse model and GMBP1 blocking group. This was attributed to the presence of the specific ligand GMBP1 on the surface of MPG NPs, which allowed more MPG NPs to enter SGC ADR cells. This
is consistent with the results of in vivo MRI. These results indicate that GMBP1 can be used as a specific peptide to monitor MDR in gastric cancer.

**In vivo synergistic therapy for orthotopic MDR gastric cancer**

The development of MDR is closely related to the TME, and tumor treatment strategies for the TME have been widely used to combat MDR. In vivo MRI has achieved accurate monitoring of MDR. The results of in vitro experiments have proven that MPG NPs can consume GSH and convert the endogenous H$_2$O$_2$ of the cell into highly toxic ·OH, thereby exerting the CDT effect. The good photothermal effect of Mn$_3$O$_4$ NPs can realize in vivo PTT, which can further enhance the CDT effect. To verify whether MPG NPs can be used for in vivo CDT/PTT synergistic therapy, an orthotopic MDR gastric cancer mouse model was established. As shown in Fig. 8A, the tumorogenesis of model mice was monitored by bioluminescence imaging, and synergistic therapy was performed for 20 days when the tumor size increased to an appropriate size. 6 h after the injection, the tumor sites of the mice in the PTT group were irradiated with an 808 nm laser. The bioluminescence imaging images of the mice were obtained 12 h after irradiation, and the weight changes of the mice were recorded. Figure 8B shows the simple principle of synergistic therapy. MPG NPs gather at the tumor site with abundant blood vessels through the EPR effect and the specific targeting effect of GMBP1 along with the blood circulation. Under irradiation with an 808 nm laser, Mn$_3$O$_4$@PDA NPs convert light energy into heat energy and locally release heat, thereby causing tumor cell apoptosis. The released Mn$_3$O$_4$ NPs react with GSH in tumor cells to generate Mn$^{2+}$, Mn$_2$O$_4^{2+}$ and H$_2$O$_2$ in tumor cells mediate the Fenton-like reaction under HCO$_3^-$ conditions to produce highly toxic ·OH, thereby killing tumor cells. The consumption of GSH by Mn$_3$O$_4$ also inhibits the elimination of ·OH by GSH to achieve a better CDT effect.

Figure 8C shows the bioluminescence images of each group of mice after 20 days of treatment. In the PBS group, the signal at the tumor site gradually increased, indicating that the tumor gradually became larger without treatment. After PBS injection and 808 nm laser irradiation, the signal at the tumor site also showed a gradual increase, but the signal was weaker than that in the PBS group. This indicates that laser irradiation alone can slow down the growth of the tumor to a certain extent, but the therapeutic effect is not better because of the low temperature. The bioluminescence signal of the mice injected with Mn$_3$O$_4$@PDA NPs was weak, but the tumor was not suppressed. This is because the injection of Mn$_3$O$_4$@PDA NPs alone can only have a tumor treatment effect through CDT. The tumors of mice injected with MPG NPs became significantly smaller because the surface of GMBP1 gave MPG NPs better tumor targeting ability, causing more MPG NPs to accumulate in the tumor site to achieve a better CDT effect. After the injection of MPG NPs and laser irradiation, the tumor bioluminescence signal of mice was significantly reduced, the tumor gradually decreased, and the tumor disappeared finally. This is because the Mn$_3$O$_4$ NPs exert a good photothermal effect under laser irradiation. Surface-wrapped PDA also enhances the PTT effect and combines with the CDT effect of MPG NPs to achieve a better synergistic therapy effect. The quantitative signal intensity of bioluminescence is shown in Additional file 1: S4A–E. Figure 8D shows a picture of the tumor after anatomy. The tumors in the MPG NPs+laser group were the smallest, and among the 5 experimental mice, the tumors in 2 mice disappeared and recovered completely. The quantitative results of tumor weight in Additional file 1: S4F also showed the same results. The tumor weight of the MPG NPs+laser group was significantly different from that of the other groups. During the treatment period, the body weight changes of the mice in each group were monitored. As shown in Additional file 1: S4G, the mice in the PBS group were weakened due to the gradual enlargement of tumors, which led to significant weight loss. The weight of the mice in the MPG NPs+laser group also gradually increased due to the recovery of their physical condition. These results indicate that MPG NPs have a good synergistic therapeutic effect. The tumors of each group of mice were sectioned and stained for observation. As shown in Fig. 8E, the H&E staining results showed that the tumor cell structure of the mice in the MPG NPs+laser group was destroyed and showed a necrotic form. The results of TUNEL staining (Fig. 8E and Additional file 1: S4H) showed that the tumor apoptosis of mice in the MPG NPs+laser group was the most severe, which was consistent with the results of in vivo synergistic therapy. All of the above results show that MPG NPs have good synergistic therapy effect and can be used for CDT/PTT synergistic therapy for gastric cancer MDR.

**In vivo biosafety assessment**

To investigate the in vivo toxicity of MPG NPs, acute toxicity and hemolysis tests were carried out. Additional file 1: S5A shows the hemolysis rate of various materials. Among them, the hemolysis rate of Mn$_3$O$_4$@PEG NPs is approximately 10%, which indicates certain blood toxicity. The hemolysis rates of MPG NPs, PDA and GMBP1 were 1.8%, 2% and 0.7%, respectively. The results show that they are almost nontoxic, further indicating that MPG NPs can be used for in vivo studies. Then, an
Fig. 8  In vivo synergistic therapy. **A** synergistic therapy strategy for 20 days. **B** Schematic diagram of in vivo synergistic therapy. **C** Bioluminescence images of mice in each group within 20 days. **D** Photos of tumors in each group of mice. **E** H&E staining and TUNEL staining images of tumor sections of mice in each group.
in vivo acute toxicity test was carried out. Three groups of healthy mice were injected with GMBP1, Mn₃O₄@PDA NPs and MPG NPs at a concentration of 50 mg kg⁻¹. The survival and body weight changes of the mice within 14 days were observed. The results showed that all 30 mice survived after 14 days. The body weight of each group of mice shown in Additional file 1: Fig. S5B exhibits a steady upward trend. The pathological changes of mice in each group were recorded within 14 days. As shown in Additional file 1: Fig. SSC, the mice in each group showed pathological changes to a certain extent, such as coarse hair, bulgy eyeballs, and bradykinesia, but this situation was improved after a week, this may be due to the toxicity of high concentrations of manganese ions. The specific statistical results of the pathological characteristics of mice in each group are shown in Additional file 1: Table S1. Among them, the pathological characteristics of mice in the Mn₃O₄@PDA NP treatment group were more obvious than those in the GMBP1 and MPG NP treatment groups. The pathological section in Additional file 1: Fig. S5D shows that GMBP1, Mn₃O₄@PDA NPs and MPG NPs exerted no obvious damage on the heart, liver, or kidneys of mice. This is due to the good tumor cell targeting of MPG NPs, which allows them to accumulate more in the tumor site, avoiding damage to normal tissues. The above results all indicate that MPG NPs have good biosafety.

Conclusions

Postoperative chemotherapy of gastric cancer easily causes MDR, which seriously affects the therapeutic effect. Therefore, accurate monitoring of MDR is very important for the treatment of gastric cancer. In past studies, existing MDR detection methods could not reflect the real state of MDR well to some extent. Therefore, it is necessary to explore new methods for real-time monitoring of MDR. Once MDR is accurately detected, individualized treatment can be performed on patients to greatly improve the survival rate. In view of this, a GMBP1 cross-linked TME-responsive self-enhanced Mn₃O₄ nanoplaform (MPG NPs) was established, which can react with GSH in tumor cells to produce Mn²⁺ to enhance T1-weighted MRI and mediate in vivo MDR monitoring. In vitro MRI results showed MRI signal enhancement activated by acidic pH, H₂O₂ and GSH. In vivo MRI results also showed that MPG NPs can specifically target SGC 7901 ADR tumors, which indicated that MPG NPs can be used for in vivo MDR monitoring. Furthermore, MPG NPs have good chemodynamic activity, which can convert the endogenous H₂O₂ of tumor cells into highly toxic -OH through a Fenton-like reaction at acidic pH to play the role of CDT. In addition, Mn₃O₄ NPs can be used as photothermal conversion agents for tumor PTT, which significantly enhances the CDT effect. A series of in vivo and in vitro experiments have shown that MPG NPs demonstrate a good inhibitory effect and synergistic therapeutic effect on tumor cells. Furthermore, MPG NPs have good biocompatibility, providing a good nanoplatform for real-time monitoring and precise diagnosis and treatment of gastric cancer MDR.

Materials and methods

Reagents

Manganese acetate (Mn(CH₃COO)₂, 98%), DSPE-PEG₂₀₀₀-NH₂ and reduced L-glutathione (GSH) were purchased from Sigma–Aldrich. Oleic acid, oleylamine, dopamine hydrochloride, methylene blue (MB), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), fluorescein diacetate (FDA) and paraformaldehyde (4%) were purchased from Aladdin. 4',6-Diamidino-2-phenylindole (DAPI) was purchased from Boster Biological Technology. 2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA) was purchased from Solarbio. Propidium iodide (PI) was purchased from Beyotime Biotechnology. The H&E staining kit and Annexin V-FITC apoptosis detection kit were purchased from Servicebio. Vinyl-modified GMBP1 (GMBP1-Ack) was synthesized by GL Biochem (Shanghai) Ltd.

Preparation of MPG NPs

Mn₃O₄ NPs were synthesized according to a previous thermal decomposition method [30]. Manganese acetate (0.17 g), oleic acid (640 µL) and oleylamine (3.28 mL) were mixed and dissolved in xylene (15 mL). The reaction was stirred at 90 °C for 10 min, and then 1 mL of DI water was added to react for an additional 2.5 h. After the reaction, 40 mL of absolute ethanol was added, and the precipitate was collected by centrifugation and dispersed in cyclohexane to obtain Mn₃O₄ NPs. Mn₃O₄@PDA NPs were synthesized according to a previous method [45]: 300 µL of Tween 20 was added dropwise to 20 mL of DI water and stirred at room temperature for 30 min. Next, 500 µL of Mn₃O₄ dispersed in cyclohexane (15.6 mg mL⁻¹) was added and sonicated for 1 h until the solution was clear. 2 mL of dopamine hydrochloride solution (1 mg mL⁻¹, pH 8.5 tris HCl) was added and stirred overnight at room temperature. The precipitate (Mn₃O₄@PDA NPs) was collected by centrifugation (14,000 rpm, 15 °C, 2 h) and dispersed in 1.56 mL of DI water.

The tetrazole compound N-(2-aminoethyl)-4-(2-(4-methoxyphenyl)-2 H-tetrazol-5-yl)-benzamide (T) was synthesized according to a previous method [46]: 5
mmol methyl 4-formylbenzoate dissolved in 60 mL of absolute ethanol. An equivalent amount of benzenesulfonyl hydrazide was added and reacted overnight. The product was filtered with suction and washed with absolute ethanol. The product was dried to obtain Schiff base. 4-Methoxybenzeneamine at 2.5 mmol was dissolved in 5 mL of a mixed solution of absolute ethanol and water (1:1). Then, 0.5 mL of concentrated hydrochloric acid was slowly added dropwise under an ice bath and stirred for 10 min. An aqueous solution of 2.6 mmol sodium nitrite was slowly added dropwise, and stirring was continued for 1 h under an ice bath. At the end of the reaction, the solution was slowly added to a pyridine solution containing 2.5 mmol Schiff base and reacted overnight. After adding an equal volume of water, a large amount of solids precipitated out, were filtered and washed with a mixed solution of ether and ethyl acetate to obtain a pink solid, which was dried for further use. Then, 0.1 mmol of pink solid was suspended in 10 mL of ethylenediamine and reacted in a water bath at 80 °C for 12 h. The product was concentrated under reduced pressure and purified by a column with methanol and dichloromethane to obtain the product T. The DMSO solution (2.13 µg mL⁻¹, 200 µL) of the tetrazole compound T was added dropwise to the Mn₃O₄@PDA NP aqueous solution (5 mg mL⁻¹, 200 µL) and reacted overnight at room temperature. The reaction solution was purified by PD-10 to obtain Mn₃O₄@PDA-T NPs. The peptide GMBP1 was added to the Mn₃O₄@PDA-T NP solution (T:GMBP1 = 1:10) and reacted overnight at room temperature. The reaction solution was purified by PD-10 to obtain MPG NPs.

**Preparation of Mn₃O₄@PEG NPs**

Mn₃O₄@PEG NPs were synthesized according to the literature [30]. One milliliter of Mn₃O₄ NPs (cyclohexane) was added to 1 mL of absolute ethanol, and the precipitate was left after centrifugation and dispersed in 3 mL of chloroform. Then, 25 mg of DSPE-PEG₂₀₀₀-NH₂ was added and reacted at room temperature for 2 h. The chloroform was dried with N₂, and the product was quickly dissolved in 10 mL of DI water to obtain Mn₃O₄@PEG NPs.

**Characterization of MPG NPs**

The successful synthesis of Mn₃O₄ NPs was characterized by XRD and TEM images. The synthesis of Mn₃O₄@PDA NPs was characterized by TEM images. The hydration particle size and zeta potential data were obtained by a Malvern particle size analyzer. The synthesis of tetrazolium compound T was characterized by mass spectrometry, nuclear magnetism, ultraviolet absorption spectroscopy and fluorescence spectroscopy. The successful synthesis of MPG NPs was characterized by ultraviolet absorption spectroscopy and fluorescence spectroscopy. The MRI images and T1 relaxation rates of Mn₃O₄ NPs and Mn₃O₄@PDA NPs under different conditions were obtained by a magnetic resonance imager (Numai). The in vitro stability of MPG NPs was measured by the change in particle size of samples dispersed in PBS and 10% FBS within 6 days at different temperatures (25 and 37 °C).

**In vitro fluorescence imaging of MPG NPs**

A PerkinElmer IVIS system was used to detect the fluorescence signal of MPG NPs. The laser excitation wavelength was 420 nm, and the emission wavelength was 570 nm. MPG NPs were diluted into different concentration gradients and placed in a black 96-well plate to obtain fluorescence images corresponding to different concentrations. The fluorescence intensity values of different concentrations were extracted for normalization.

**T1-weighted MRI of MPG NPs and determination of relaxation constant r₁**

The T1 relaxation time and T1-weighted images of MPG NPs and Mn₃O₄@PDA NPs were measured with a 0.5 T small animal magnetic resonance scanner. The measurement method was as follows: MPG NPs or Mn₃O₄@PDA NPs were diluted into 5 concentration gradients and placed in a 200 µL centrifuge tube to obtain the T1 relaxation time corresponding to different concentrations. The parameters of the conventional spin echo acquisition sequence were set as follows: TR = 400 ms, TE = 18.2 ms, slice gap = 0.8 mm, slice width = 3 mm. The value of r₁ was calculated by linear fitting of 1/T1 (s⁻¹) to the concentration of Mn₃O₄ NPs (mM).

To verify the T1-weighted MRI properties of MPG NPs, relaxation images and relaxation time were acquired using an MRI instrument. The relaxation images and relaxation time of MPG NPs at different concentrations and different pH values (pH 7.4, pH 6, pH 5) were determined, and a line graph of the relaxation rate according to the relaxation time was drawn. DI water samples without MPG NPs served as controls. To verify that the increase in Mn²⁺ can enhance T1-weighted MRI, the relaxation images and relaxation time of MPG NP samples with or without H₂O₂ were measured. MPG NP solutions of different Mn concentrations were mixed with GSH and reacted for 10 min to obtain MRI images and relaxation times.

**In vitro and in vivo photothermal effect of MPG NPs**

The photothermal effect of MPG NPs was verified by measuring the changes in temperature of different materials, different irradiation powers, and different concentrations. First, the temperature changes of different
samples (H$_2$O, Mn$_3$O$_4$@PEG NPs, PDA, MPG NPs) with the same concentration were measured after 5 min of 808 nm laser irradiation. Then, the temperature changes of the same concentration of Mn$_3$O$_4$@PEG NPs and MPG NPs under different powers (0.5 W, 1 W, 2 W) of the 808 nm laser were measured. Finally, the temperature changes of different concentrations of Mn$_3$O$_4$@PEG NPs and MPG NPs were measured after 808 nm laser irradiation for 5 min. In addition, an 808 nm laser was used to irradiate MPG NPs for 5 min, the temperature was then lowered to room temperature, and 5 cycles were carried out to observe the photothermal stability of MPG NPs.

An orthotopic mouse model of SGC 7901 ADR was established. The mice in the control group were injected with 200 µL of PBS intravenously, and the mice in the experimental group were injected with 200 µL of Mn$_3$O$_4$@PDA NPs and 200 µL of MPG NPs (the concentration of Mn$_3$O$_4$ was 5 mg mL$^{-1}$). After 6 h, the tumor site was irradiated with an 808 nm laser (2 W) for 3 min, and photothermal images of mice in each group were obtained.

- OH generation by Mn$^{2+}$-mediated Fenton-like reaction

A 25 mM NaHCO$_3$/5% CO$_2$ buffer solution containing methylene blue (MB, 10 µg mL$^{-1}$), H$_2$O$_2$ (8 mM), and Mn(CH$_3$COO)$_2$ (0.5 mM) was reacted at 37 °C for 30 min. The UV absorption spectrum of the sample was measured with a UV spectrophotometer to verify that the -OH generated by the Fenton-like reaction induced MB degradation. In addition, different concentrations of H$_2$O$_2$ and Mn$^{2+}$ were used to obtain the UV absorption spectrum of MB.

The scavenging effect of GSH on -OH

In the mixture of MB (10 µg mL$^{-1}$), H$_2$O$_2$ (8 mM), Mn(CH$_3$COO)$_2$ (0.5 mM) and 25 mM NaHCO$_3$/5% CO$_2$, GSH (10 mM) was added or not to observe the degradation of MB and verify the scavenging effect of GSH on -OH. In addition, different concentrations of GSH (0–10 mM) were used to verify the scavenging effect of GSH on -OH.

Chemodynamic activity of Mn$_3$O$_4$@PEG NPs and MPG NPs

Different concentrations of GSH were added to the Mn$_3$O$_4$@PEG NP solution, the color change of the solution was observed, and the ability of GSH to react quickly with Mn$_3$O$_4$ to generate Mn$^{2+}$ was verified. In the mixture of MB (10 µg mL$^{-1}$), H$_2$O$_2$ (8 mM), Mn$_3$O$_4$@PEG NPs ([Mn]$=0.5$ mM), MPG NPs ([Mn]$=0.5$ mM) and 25 mM NaHCO$_3$/5% CO$_2$, different concentrations of GSH were added to observe the degradation of MB.

In vitro ROS production

SGC 7901 ADR cells were placed in a culture flask for culture, the medium was changed to 50-60%, and the corresponding materials were added to continue culturing for 12 h in a 37 °C incubator. The groups were divided as follows: (1) control; (2) Mn(CH$_3$COO)$_2$: 20 µg mL$^{-1}$; (3) MPG NPs: 10 µg mL$^{-1}$; and (4) MPG NPs: 20 µg mL$^{-1}$. After 12 h, the medium was removed, and the cells were trypsinized and washed with 1 mL of PBS. DCFH-DA solution (10 µM) was added to each group and incubated for 30 min at 37 °C. The supernatant was removed by centrifugation, and the cells were dispersed in 300 µL of PBS. The suspended cells were dropped into a confocal dish, and the fluorescence of DCF was observed by confocal microscopy. The MFI was quantified by Image J software.

Cell lines and orthotopic gastric cancer mice model

Luciferase-labeled gastric cancer cell lines (SGC 7901-Luc and SGC 7901 ADR-Luc) were donated by Xijing Hospital. All cells were cultured in 10% FBS medium and incubated at 37 °C in a 5% CO$_2$ atmosphere. Severe combined immunodeficiency (SCID) mice (4 weeks old, approximately 16 g) were purchased from the Experimental Center of Xi’an Jiaotong University. Mice were fed under SPF conditions. An orthotopic mouse model of gastric cancer was used for in vivo MRI and synergistic therapy. 100 µL of SGC 7901-Luc or SGC 7901 ADR-Luc cells ($5 \times 10^6$ cells/mL) was injected into the stomach wall of mice through surgery. After injection, mice were fed under SPF conditions. The size of the tumor was monitored by bioluminescence imaging. All animals were kept in accordance with the Guidelines for Use and Care of Animals at Xi’an Jiaotong University (Number XJTULAC 2016 – 412).

Cellular uptake and affinity analysis

SGC 7901 ADR cells in the logarithmic growth phase were seeded in a confocal dish ($1 \times 10^5$ cell/well) and cultured for 48 h. The medium was removed, and 1 mL of PBS solution containing MPG NPs was added after the cells adhered to the wall. The cells were incubated at 37 °C for different times (1 h, 3 h, 6 h, 9 h). The medium was removed and washed with PBS. Then, 1 mL of 4% paraformaldehyde was quickly added to fix the cells for 20 min. The solution was removed, and the cells were washed 3 times with water. Then, 500 µL of DAPI was added for staining for 15 min. The cells were washed with water 3 times to remove the DAPI dye solution and observed qualitatively with a confocal microscope. For the affinity experiment, the adherent cells were divided into 4 groups. The first group was SGC 7901 ADR cells, which were incubated with MPG NPs for 6 h. The second group was SGC 7901 cells, which were incubated with MPG NPs for 6 h. The third and fourth groups were SGC 7901 cells and SGC 7901 ADR cells, respectively, which
were incubated with GMBP1 for 6 h first and then incubated with MPG NPs for an additional 6 h. The nucleus was stained with DAPI and qualitatively observed with a confocal microscope. All confocal images were quantitatively analyzed using Image J software.

**Cell inhibition of MPG NPs**

The cell suspension (3 cell lines) was added to 96-well plates and incubated for 24 h (37 °C, 5% CO₂). 100 µL per well. Samples (Mn₃O₄@PDA NPs, T, GMBP1, Mn₃O₄@PDA-T NPs, MPG NPs) of different concentrations were added to different wells and incubated for 24 h. The medium was removed, the cells were washed 3 times with PBS, and new medium was added. Next, 10 µL of MTT solution was added to each well. After incubation for 2 h, a microplate reader was used to measure the absorbance at 490 nm. The cell survival rate was calculated according to the formula:

\[
\text{Cell viability} = \frac{\text{OD}_{\text{MPG NPs}} - \text{OD}_{\text{black}}}{\text{OD}_{\text{control}} - \text{OD}_{\text{black}}} \times 100\% \quad (1)
\]

To verify the effect of laser irradiation on the cell survival rate, the cells were incubated with different concentrations of MPG NPs for 3 h and then irradiated with an 808 nm laser for 5 min (2 W, 5 cm distance). Cells treated without MPG NPs were used as controls. The cells were incubated for 24 h. The cell survival rate was calculated.

**Colony formation**

The inhibitory effect of MPG NPs was evaluated by colony formation experiments. The cells were seeded in a 6 cm petri dish containing 10 mL of prewarmed medium, with 500 cells per well. Different concentrations of MPG NPs were added to different petri dishes, and petri dishes with DMSO were added as controls. The cells were irradiated with an 808 nm laser for 5 min (irradiation distance 5 cm). The petri dish was placed in an incubator at 37 °C and incubated for 48 h. The medium was changed, and the cells were incubated for 5 days (37 °C, 5% CO₂). The medium was removed, and the cells were carefully washed twice with PBS. Then, 4% paraformaldehyde solution was added to fix the cells for 15 min. The solution was removed, and crystal violet staining solution was quickly added. After dyeing, the excess dye solution was rinsed slowly with DI water. After the petri dish was dry, the cells were photographed and counted.

**Flow cytometry**

Flow cytometry was used to detect cell apoptosis after treatment with different concentrations of MPG NPs. The cells were seeded in 24-well plates, and different concentrations of MPG NPs were added. An 808 nm laser was used to irradiate the cells for 2 min with a power of 2 W. The cells treated without MPG NPs were used as a control. The cells were placed in an incubator and incubated for 6–8 h. The cells were collected and washed with PBS and then resuspended in PBS. The cells were stained with Annexin V FITC for 1 h and then stained with PI for 30 min. A FACScan system was used to analyze the stained cells.

**In vitro photothermal effect of MPG NPs**

SGC 7901 ADR cells were inoculated in 96-well plates, the medium was removed when the cells grew to 50-60%, and the cells were washed once with PBS. MPG NP solution was added (final concentration of 100 µM). Cells incubated without MPG NPs were used as controls. The cells in the experimental group were irradiated with an 808 nm laser for 5 min and then cultured in an incubator for 8 h. The culture medium was removed, and the cells were washed once with PBS and stained with FDA and PI. FDA (5 µg mL⁻¹) and PI (5 µg mL⁻¹) solution were added to each well and incubated for 10 min at 37 °C in the dark. After incubation, fluorescent staining was observed under a fluorescence microscope. FDA-positive cells showed green fluorescence, and PI-positive cells showed red fluorescence.

**In vivo T1-weighted MRI and immunofluorescence staining**

SGC 7901 ADR-Luc and SGC 7901-Luc orthotopic tumor-bearing mouse models were established. The tumor size was monitored by bioluminescence imaging. Mice were intraperitoneally injected with luciferase substrate (75 mg kg⁻¹), and bioluminescence imaging was performed 10 min later to observe the tumor size. In vivo T1-weighted MRI was performed when the tumor grew to an appropriate size. The tumor-bearing mice were divided into four groups (n = 3). The mice were placed in a magnetic resonance imager (Philips ingenia 3.0 T) for imaging, and MRI images were obtained. Mice in different experimental groups were injected with different nanomaterials. SGC 7901 ADR tumor-bearing mice and SGC 7901 tumor-bearing mice were injected intravenously with MPG NPs (50 mg kg⁻¹). Mice in the blocking group were injected with 100 µL of GMBP1 (1 mg mL⁻¹) through the tail vein first and then injected with MPG NPs (50 mg kg⁻¹) half an hour later. In vivo MRI was performed at different times (1 h, 2 h, 3 h, 4 h, 5 h) after injection, and MRI images before the injection were also obtained. Signal extraction was performed on the tumor area, and the signal changes at the tumor site were quantitatively observed. After in vivo imaging, the main organs (heart, liver, and kidney) and tumor tissues of each group of mice were collected, frozen and sectioned, and histological analysis was performed by conventional immunofluorescence staining [47]. Rabbit anti-human GRP78 and FITC-labeled goat anti-rabbit antibodies were
used for MPG NP visualization, and the nuclei were labeled with DAPI. CLSM was used to observe tissue sections. References: As per pubmed findings, citation details for Reference (19, 25) have been inserted. Kindly check and confirm the inserted details. Author has been changed the references and confirmed details. [19] Sahai N, Ahmad N, Gogoi M. Nanoparticles based drug delivery for tissue regeneration using biodegradable scaffolds: a review. Curr Pathobiol Rep. 2018;6:219-24. [25] Ahmad N, Gopinath P, Dutta R. 3D printing technology in nanomedicine. Amsterdam: Elsevier; 2019.

In vivo CDT/PTT synergistic therapy
Twenty-five orthotopic tumor-bearing mice were randomly divided into 5 groups (n=5) as follows: (1) PBS; (2) PBS + laser; (3) Mn₃O₄@PDA NPs; (4) MPG NPs; and (5) MPG NPs + laser. Each mouse was monitored for tumor growth by bioluminescence imaging. When the tumor grew to a suitable size, in vivo synergistic therapy was conducted. Mice in different groups were injected with the corresponding nanomaterials (50 mg kg⁻¹) and received in vivo synergistic therapy, with intervention every three days. Six hours after the injection of the corresponding nanomaterials, the mice in the PBS + laser group and MPG NPs + laser group were irradiated with an 808 nm laser (2 W) to the tumor sites for 3 min for PTT (irradiation distance was 5 cm). After 12 h, all groups of mice were subjected to bioluminescence imaging, and the body weight data of each mouse were obtained. The changes in tumors were continuously monitored for 20 days. After 20 days, the mice in each group were sacrificed, and tumor tissues of the mice were obtained, photographed, fixed with 4% paraformaldehyde, and then paraffin sectioned. H&E staining was performed on the tumors of mice, and TUNEL staining was performed to observe the apoptosis of tumor cells.

In vivo acute toxicity and histological staining
Thirty healthy mice (15 female mice and 15 male mice) were randomly divided into three groups, and each group contained 5 female mice and 5 male mice. The first group of mice was injected with 200 µL of GMBP1 (1 mg mL⁻¹) as a control, the second group of mice was injected with 200 µL of Mn₃O₄@PDA NPs (50 mg kg⁻¹), and the third group of mice was injected with 200 µL of MPG NPs (50 mg kg⁻¹). The body weight and death of each group of mice within 14 days were recorded, and the survival rate of the mice was calculated. After 14 days, the mice were dissected, and the major organs of the mice were taken for H&E staining.

Hemolysis test
Whole blood of mice was obtained and added to Triton X-100 (1% V/V), Mn₃O₄@PEG NPs, MPG NPs, PDA, and GMBP1 and incubated at 37 °C for 2 h. The blood samples were centrifuged at 13,000 rpm for 15 min, the supernatant was taken, the absorbance at 540 nm was measured with an ultraviolet spectrophotometer, and the hemolysis rate was calculated.

Statistical analysis
The data represent three or more independent experiments. Statistical analysis was performed using analysis of variance. p < 0.05 was considered indicative of a significant difference. All statistical analyses were performed using GraphPad Prism software.

Abbreviations
MDR: Multidrug resistance; MRI: Magnetic resonance imaging; CDT: Chemo-dynamic therapy; TME: Tumor microenvironment; PTT: Photothermal therapy; H₂O₂: Hydrogen peroxide; -OH: Hydroxyl radicals; NPs: Nanoparticles; MB: Methylene blue; FDA: Fluorescein diacetate; PI: Propidium iodide; MFI: Mean fluorescence intensity.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1186/s12951-022-01441-6.

Additional file 1: Figure S1. Synthesis and characterization of tetrazole compound. (A) Synthesis of tetrazole compound. (B) Mass spectrum of tetrazole compound. (C) ¹³C NMR of tetrazole compound. Figure S2. In vitro chemodynamic activity of MPG NPs. (A) The remaining percent of MB after different treatments. (B) Photographs of Mn₃O₄@PEG NPs after exposure to different concentrations of GSH. (C) Photographs of Mn₃O₄@PEG NPs reacted with GSH for 5 min and dispersed in aqueous solutions of different pH for different times. (D) The remaining percent of MB after different concentrations of MPG NPs. (E) The remaining percent of MB after different concentrations of Mn₃O₄@PEG treatment. (F) MB degradation efficiency after treatment of different samples. (G) Quantification of DCF fluorescence in SGC 7901 ADR cells after different sample treatments. Figure S3. Cell uptake and affinity analysis, and in vivo and in vitro quantitative results. (A) Fluorescence images of SGC 7901 ADR cells incubated with MPG NPs for different times. (B) Fluorescence of SGC 7901 and SGC 7901 ADR cells with or without GMBP1 blockade. (C) Quantification of the fluorescence intensity of SGC 7901 ADR cells incubated with MPG NPs for different times. (D) Quantification of the fluorescence intensity of SGC 7901 and SGC 7901 ADR cells incubated with or without GMBP1 blockade. (E) Quantification of in vivo MRI signal intensity. Figure S4. Quantitative results of in vivo synergistic therapy. (A)-(E) Quantification of bioluminescence imaging signal intensity in each group of mice within 20 days. (F) Tumor weight of mice in each group. (G) Changes in body weight of mice in each group within 20 days. (H) Number of TUNEL-positive cells in tumor sections of mice in each group. Figure S5. In vivo toxicity of MPG NPs. (A) Hemolysis rate of Mn₃O₄@PEG, PDA, GMBP1 and MPG NPs. (B) Body weight changes of mice within 14 days. (C) Pathological features of mice within 14 days. (D) H&E staining images of the heart, liver and kidney of different groups of mice. Table S1. Statistical analysis of pathological manifestations of mice within 14 days.

Acknowledgements
Not applicable.
Author contributions
HRL, XCC and YH conceived and designed the experiments. HRL, XCC and TY carried out the experiments. YZ, JWM, LI, LJP and NL contributed to analyze the experimental results. HRL and YHZ wrote the manuscript. All authors have read and approved the final manuscript.

Funding
This work was supported in part by the National Natural Science Foundation of China under Grant Nos. 11727813, 32010174, 32171173, the Open Funding Project of National Key Laboratory of Human Factors Engineering Grant No. SYFD061908K, the Fundamental Research Funds for the Central Universities under Grant No. JB211206, and the Shanghai Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences (2018YQ33).

Availability of data and materials
All data generated or analyzed during this study are available in the manuscript or supplementary information.

Declarations

Ethics approval and consent to participate
All animals were kept in accordance with the Guidelines for Use and Care of Animals at Xi’an Jiaotong University (Number XJTULAC 2016—412).

Competing interests
The authors declare that they have no competing interests.

Received: 17 January 2022 Accepted: 26 April 2022
Published online: 23 May 2022

References
1. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The global burden of cancer 2013 global burden of disease cancer collaboration. Jama Oncol. 2015;1(4):505–27.
2. Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT, et al. Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med. 2016;5(7):1444–53.
3. Qi M, Liu D, Zhang S. MicroRNA-21 contributes to the discrimination of chemoresistance in metastatic gastric cancer. Cancer Biomark. 2017;18(4):451–8.
4. Liu M, Zheng S, Zhang X, Guo H, Shi X, Kang X, et al. Cerenkov luminescence imaging on evaluation of early response to chemotherapeutic drug-resistant gastric cancer. Nanomed Nanotechnol. 2018;14(1):205–13.
5. Kang J, Zhao G, Lin T, Tang S, Xu G, Hu S, et al. A peptide derived from phage display library exhibits anti-tumor activity by targeting GRP78 in gastric cancer multidrug resistance cells. Cancer Lett. 2013;339(2):247–59.
6. Wang X, Li Y, Xu G, Liu M, Xue L, Liu L, et al. Mechanism study of peptide GMBP1 and its receptor GRP78 in modulating gastric cancer MDR by iTRAQ-based proteomic analysis. BMC Cancer. 2015;15:358.
7. Zhan W, Cai X, Li H, Du G, Hu H, Wu Y, et al. GMBP1 conjugated manganese oxide nanoparticles for in vivo monitoring of gastric cancer MDR using magnetic resonance imaging. RSC Adv. 2020;10(23):13687–95.
8. Gemici C, Sargin M, Uygur-Bayramici O, Mayadagli A, Yaprak G, Dabak R, et al. Risk of endocrine pancreatic insufficiency in patients receiving adjuvant chemoendocrine for resected gastric cancer. Radiother Oncol. 2013;107(2):195–9.
9. Lippert TH, Ruff HJ, Volm M. Intrinsic and acquired drug resistance in malignant tumors. Arzneimittelforschung. 2008;58(6):261–4.
10. Guo Y, Zhang X, Sun W, Jia H-R, Zhu Y-X, Zhang X, et al. Metal-phenolic network-based nanocomposites that evoke ferroptosis by apoptosis: promoted nuclear drug influx and reversed drug resistance of cancer. Chem Mater. 2019;31(24):10071–84.
11. Liu C, Zhang C, Wang P, Zhao Y, Yang Y, Wang Y, et al. Light-free generation of singlet oxygen through manganese-thiophene nanosystems for pH-responsive chemiluminescence imaging and tumor therapy. Chem. 2020(60):2314–34.
12. Lin L, Song J, Song L, Ke K, Liu Y, Zhou Z, et al. Simultaneous Fenton-like ion delivery and glutathione depletion by MnO2-based nanoagent to enhance chemodynamic therapy. Angew Chem Int Ed. 2018;57(18):4902–6.
13. Tang Z, Zhang H, Liu Y, Ni D, Zhang H, Zhang J, et al. Antiferromagnetic pyrite as the tumor microenvironment-mediated nanoplatform for self-enhanced tumor imaging and therapy. Adv Mater. 2017;29(47):1701683.
14. Arricó B, Nathan C. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 1984;44(10):4232–42.
15. Abbasi Rajani A, Haghjooj Yavarnamad S, Asadnia M, Razmjou A. Recent advances in nanomaterials development for nanomedicine and cancer. ACS Appl Bio Mater. 2021;4(8):5908–25.
16. Abdelhamid H. Zeolitic imidazolate frameworks (ZIF-8) for biomedical applications: a review. Curr Med Chem. 2021;28(34):7023–75.
17. Ahtlawat J, Barroso GG, Asl SM, Alvarado M, Armendariz I, Bernal J, et al. Nanocarriers as potential drug delivery candidates for overcoming the blood-brain barrier: challenges and possibilities. ACS Omega. 2020;5(22):12583–95.
18. Thakooan A, Khan F, Ahmad N, Shaikh S, Rizvi S, Shalik S, et al. Silver nanoparticles from leaf extract of Mentha piperita: eco-friendly synthesis and effect on acetylcholinesterase activity. Life Sci. 2018;209:430–4.
19. Sahai N, Ahmad N, Gogo M. Nanoparticles based drug delivery for tissue regeneration using biodegradable scaffolds: a review. Curr Pathobiol Rep. 2018;6:219–24.
20. Ahmad N, Bhatnagar H, Ali S, Dutta R. Phytofabrication of bioinduced silver nanoparticles for biomedical applications. Int J Nanomed. 2015;10:7019–30.
21. Ahmad N, Bhatnagar S, Saxena R, Iqbal D, Ghosh AK, Dutta R. Biosynthesis and characterization of gold nanoparticles: kinetics, in vitro and in vivo study. Mat Sci Eng C Mater. 2017;78:553–64.
22. Sahai N, Gogo M, Ahmad N. Mathematical modeling and simulations for developing nanoparticle-based cancer drug delivery systems: a review. Curr Pathobiol Rep. 2021;9(1):1–8.
23. Ahmad N, Bhatnagar S, Dubey SD, Saxena R, Sharma S, Dutta R. Nano-packaging in food and electronics. In: Ranjan S, Dasgupta N, Lichtfouse E, editors. Nanoscience in food and agriculture 1. Cham: Springer International Publishing; 2017. p. 45–97.
24. Ahmad N, Gopinath P. Intelligent nanomaterials for drug delivery applications. Amsterdam: Elsevier; 2020.
25. Ahmad N, Gopinath P, Dutta R. 3D printing technology in nanomedicine. Amsterdam: Elsevier; 2019.
26. Cai X, Zhu Q, Zeng Y, Zeng Q, Chen X, Zhan Y. Manganese oxide nanoparticles as MRI contrast agents in tumor multimodal imaging and therapy. Int J Nanomed. 2019;14:8321–44.
27. Wang A, Guo M, Wang N, Zhao J, Qi W, Muhammad F, et al. Redox-mediated dissolution of paramagnetic nanolids to achieve a smart theranostic system. Nanoscale. 2014;6(10):5270–8.
28. Liu Y, Zhang G, Guo Q, Ma L, Jia Q, Liu L, et al. Artificially controlled degradeable inorganic nanomaterial for cancer theranostics. Biomaterials. 2017;112:204–17.
29. Zhao Z, Xu K, Fu C, Liu H, Lei M, Bao J, et al. Interfacial engineered gadolinium oxide nanoparticles for magnetic resonance imaging guided microenvironment-mediated synergetic chemodynamic/photothermal therapy. Biomaterials. 2019;219:119379.
30. Zhan Y, Zhan W, Li H, Xu X, Cao X, Zhu S, et al. In vivo dual-modality fluorescence and magnetic resonance imaging-guided lymph node mapping with good biocompatibility manganese oxide nanoparticles. Molecules. 2017;22(12):2208.
31. Huang N, Zhang S, Yang L, Liu M, Li H, Zhang Y, et al. Multifunctional electrochemical platforms based on the michael addition/schiff base reaction of polydopamine modified reduced graphene oxide: construction and application. ACS Appl Mater Inter. 2015;7(32):17935–46.
32. Song W, Wang Y, Qu J, Maiden MM, Lin Q. A photoinducible 1,3-dipolar cycloaddition reaction for rapid, selective modification of tetrazole-containing proteins. Angew Chem Int Ed. 2008;47(15):2832–5.
33. Ho C, Ding S. Structure, properties and applications of mussel-inspired polydopamine: J Bomed Nanotechnol. 2014;10(10):3063–84.
34. Kim M, Son H, Kim G, Park K, Huh Y, Haem S. Redoxable heteronanocrystals functioning magnetic relaxation switch for activatable T-1 and T-2 dual-mode magnetic resonance imaging. Biomaterials. 2016;101:121–30.
35. Zhang Y, Tan J, Long M, Yang H, Yuan S, Tang A, et al. An emerging dual collaborative strategy for high-performance tumor therapy with mesoporous silica nanotubes loaded with Mn$_3$O$_4$. J Mater Chem B. 2016;4(46):7406–14.

36. Xu L, Han W, Yang P, Jia T, Dong S, Bi H, et al. Tumor microenvironment-responsive mesoporous MnO$_2$-coated upconversion nanoplatfor for self-enhanced tumor theranostics. Adv Funct Mater. 2018;28(36):1803804.

37. Duan B, Wang D, Wu H, Xu P, Jiang D, Xia C, et al. Core-shell structured Fe$_3$O$_4$@C@MnO$_2$ nanoparticles as pH-responsive T-1-T-2* dual-modal contrast agents for tumor diagnosis. Acs Biomater Sci Eng. 2018;4(8):3047–54.

38. Slatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991;51(3):794–8.

39. Liu J, Du P, Liu T, Wang B, Wang W, Ju H, et al. A black phosphorus/ manganese dioxide nanoplateform: oxygen self-supply monitoring, photodynamic therapy enhancement and feedback. Biomaterials. 2019;192:179–88.

40. Sun Q, He F, Sun C, Wang X, Li C, Xu J, et al. Honeycomb-satellite structured pH/H$_2$O$_2$-responsive degradable nanoplateform for efficient photodynamic therapy and multimodal imaging. Acs Appl Mater Inter. 2018;10(40):33901–12.

41. Chen Q, Feng L, Liu J, Zhu W, Dong Z, Wu Y, et al. Intelligent albumin-MnO$_2$ nanoparticles as pH/H$_2$O$_2$-responsive dissociable nanocarriers to modulate tumor hypoxia for effective combination therapy. Adv Mater. 2016;28(33):7129–36.

42. Gordijo C, Abbasi A, Amini M, Lip H, Maeda A, Cai P, et al. Design of hybrid MnO$_2$-polymer-lipid nanoparticles with tunable oxygen generation rates and tumor accumulation for cancer treatment. Adv Funct Mater. 2015;25(12):1858–72.

43. Afrin M, Frinner A, Cohen Y. Active oxygen chemistry within the liposomal bilayer part iv: locating 2′,7′-dichlorofluorescein (DCF), 2′,7′-dichlorodi-hydrofluorescein (DCFH) and 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) in the lipid bilayer. Chem Phys Lipids. 2004;131(1):123–33.

44. Ding X, Liu J, Li J, Wang F, Wang Y, Song S, et al. Polydopamine coated manganese oxide nanoparticles with ultrahigh relaxivity as nanotheranostic agents for magnetic resonance imaging guided synergetic chemo-/photothermal therapy. Chem Sci. 2016;7(11):6695–700.

45. Nafijuhaman M, Nurunnabi M, Kang SH, Reeck GR, Khan HA, Lee YK. Ternary graphene quantum dot-polydopamine-Mn$_3$O$_4$ nanoparticles for optical imaging guided photodynamic therapy and T-1-weighted magnetic resonance imaging. J Mater Chem B. 2015;3(28):5815–23.

46. Li F, Zhang H, Sun Y, Pan Y, Zhou J, Wang J. Expanding the genetic code for photoclick chemistry in Ecoli, Mammalian cells, and A.thaliana. Angew Chem Int Edit. 2013;52(37):9700–4.

47. Zhan Y, Shi S, Ehlerding E, Graves S, Goel S, Engle J, et al. Radiolabeled, antibody-conjugated manganese oxide nanoparticles for tumor vasculature targeted positron emission tomography and magnetic resonance imaging. Acs Appl Mater Inter. 2017;9(44):38304–12.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.